| Clinical treatment programs | |
| Total revenues | |
| Production/cost of goods sold | |
| Research and development | 900K |
| General and administrative | 1.64M |
| Total costs and expenses | 2.83M |
| Operating loss | -2.81M |
| Interest expense from capital leases | |
| Interest and other income | |
| Funds received from sale of income tax net operating losses (Note 13) | |
| Redeemable warrants valuation adjustment (Note 10) | |
| Net loss | |
| Basic and diluted loss per share (Note 2) | -0.01 |
| Weighted average shares outstanding, basic and diluted | |